Literature DB >> 15930283

Tumor-stromal interaction through the estrogen-signaling pathway in human breast cancer.

Yuri Yamaguchi1, Hiroyuki Takei, Kimito Suemasu, Yasuhito Kobayashi, Masafumi Kurosumi, Nobuhiro Harada, Shin-ichi Hayashi.   

Abstract

In postmenopausal breast cancers, locally produced estrogen by adipose stromal cells causes the progression of tumor growth. Although aromatase, a key enzyme of estrogen synthesis, is highly expressed in the adipose stromal cells, and aromatase inhibitors show greater efficacy in postmenopausal breast cancers, the mechanism of increasing aromatase activity in the stromal cells remains unclear. To analyze the estrogen signals and to detect the estrogen receptor (ER)-activating ability of adipose stromal cells for individual human breast cancers, we developed a new reporter cell system. To visualize the activation of ER, we first established a stable transformant, named E10, of human breast cancer MCF-7 cells by transfection with the estrogen-responsive element-green fluorescent protein (GFP) gene. E10 cells specifically express GFP when ER is activated by estrogen or by coculture with adipose stromal cells isolated from breast tumor tissues in the presence of testosterone, a substrate for aromatase. Treatment of adipose stromal cells with dexamethasone, a stimulator of aromatase gene expression, resulted in an increase in the expression of GFP in E10 cells in the coculture. Using this system, we characterized the adipose stromal cells of 67 human breast cancers and found that GFP expression levels vary among the cases, suggesting that the ability of adipose stromal cells to activate ERs is unique for individual breast cancers. High induction levels of GFP were observed more frequently in postmenopausal cases than in premenopausal cases, whereas they did not significantly correlate with the ER expression status. Aromatase inhibitors inhibited the induction of GFP expression in the coculture, but the sensitivities to the drugs varied among the individual cases. Aromatase gene expression levels in adipose stromal cells did not always correlate with their ability to induce GFP. These results suggest that this system to detect total ER activation based on the interaction with adipose stromal cells is a useful tool for analyzing local estrogen signals and for tumor-stromal interactions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15930283     DOI: 10.1158/0008-5472.CAN-04-3236

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  A Selective Ligand for Estrogen Receptor Proteins Discriminates Rapid and Genomic Signaling.

Authors:  Chetana M Revankar; Cristian G Bologa; Richard A Pepermans; Geetanjali Sharma; Whitney K Petrie; Sara N Alcon; Angela S Field; Chinnasamy Ramesh; Matthew A Parker; Nikolay P Savchuk; Larry A Sklar; Helen J Hathaway; Jeffrey B Arterburn; Tudor I Oprea; Eric R Prossnitz
Journal:  Cell Chem Biol       Date:  2019-11-06       Impact factor: 8.116

2.  (--)-Xanthatin selectively induces GADD45γ and stimulates caspase-independent cell death in human breast cancer MDA-MB-231 cells.

Authors:  Shuso Takeda; Kazumasa Matsuo; Kentaro Yaji; Shunsuke Okajima-Miyazaki; Mari Harada; Hiroko Miyoshi; Yoshiko Okamoto; Toshiaki Amamoto; Mitsuru Shindo; Curtis J Omiecinski; Hironori Aramaki
Journal:  Chem Res Toxicol       Date:  2011-05-13       Impact factor: 3.739

3.  Letrozole-induced functional changes in carcinoma-associated fibroblasts and their influence on breast cancer cell biology.

Authors:  Kaifu Li; Hua Kang; Yajun Wang; Tao Hai; Guohua Rong; Haichen Sun
Journal:  Med Oncol       Date:  2016-05-27       Impact factor: 3.064

4.  Identification of a GPER/GPR30 antagonist with improved estrogen receptor counterselectivity.

Authors:  Megan K Dennis; Angela S Field; Ritwik Burai; Chinnasamy Ramesh; Whitney K Petrie; Cristian G Bologa; Tudor I Oprea; Yuri Yamaguchi; Shin-Ichi Hayashi; Larry A Sklar; Helen J Hathaway; Jeffrey B Arterburn; Eric R Prossnitz
Journal:  J Steroid Biochem Mol Biol       Date:  2011-07-14       Impact factor: 4.292

Review 5.  Mechanisms of hormonal therapy resistance in breast cancer.

Authors:  Shin-ichi Hayashi; Mariko Kimura
Journal:  Int J Clin Oncol       Date:  2015-02-05       Impact factor: 3.402

6.  Age-correlated protein and transcript expression in breast cancer and normal breast tissues is dominated by host endocrine effects.

Authors:  Tomo Osako; Hakwoo Lee; Gulisa Turashvili; Derek Chiu; Steven McKinney; Stacey E P Joosten; Darcy Wilkinson; Torsten O Nielsen; Wilbert Zwart; Joanne T Emerman; Connie J Eaves; Carlos Caldas; Samuel Aparicio
Journal:  Nat Cancer       Date:  2020-05-11

7.  Detection of estrogen-independent growth-stimulating activity in breast cancer tissues: implication for tumor aggressiveness.

Authors:  Yuri Yamaguchi; Yuko Seino; Hiroyuki Takei; Masafumi Kurosumi; Shin-Ichi Hayashi
Journal:  Cancer Microenviron       Date:  2013-11-08

8.  Individual transcriptional activity of estrogen receptors in primary breast cancer and its clinical significance.

Authors:  Tatsuyuki Gohno; Yuko Seino; Toru Hanamura; Toshifumi Niwa; Mitsuyo Matsumoto; Nobuo Yaegashi; Hanako Oba; Masafumi Kurosumi; Hiroyuki Takei; Yuri Yamaguchi; Shin-Ichi Hayashi
Journal:  Cancer Med       Date:  2012-10-30       Impact factor: 4.452

9.  Contribution of Estrone Sulfate to Cell Proliferation in Aromatase Inhibitor (AI) -Resistant, Hormone Receptor-Positive Breast Cancer.

Authors:  Toru Higuchi; Megumi Endo; Toru Hanamura; Tatsuyuki Gohno; Toshifumi Niwa; Yuri Yamaguchi; Jun Horiguchi; Shin-Ichi Hayashi
Journal:  PLoS One       Date:  2016-05-26       Impact factor: 3.240

10.  Prognostic value of the ubiquitin ligase carboxyl terminus of the Hsc70-interacting protein in postmenopausal breast cancer.

Authors:  Sasagu Kurozumi; Yuri Yamaguchi; Shin-Ichi Hayashi; Hiromi Hiyoshi; Tetsuji Suda; Tatsuyuki Gohno; Hiroshi Matsumoto; Hiroyuki Takei; Jun Horiguchi; Izumi Takeyoshi; Tetsunari Oyama; Masafumi Kurosumi
Journal:  Cancer Med       Date:  2016-06-23       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.